February 27, 2017 11:33 PM ET

Biotechnology

Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of resea...

34175 Ardenwood Boulevard

Suite 200

Fremont, CA 94555

United States

Founded in 2007

93 Employees

Phone:

510-745-1700

Fax:

510-745-0493

Key Executives for Ardelyx, Inc.

Chief Executive Officer and President
Age: 51
Total Annual Compensation: $470.0K
Chief Financial Officer and Treasurer
Age: 48
Total Annual Compensation: $320.0K
General Counsel and Senior Vice President
Age: 52
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2015.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016

Ardelyx, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported Loss from operations was $31,476,000 against loss from operations of $16,876,000 a year ago. Net loss was $31,276,000 against net loss of $17,000,000 a year ago. Net loss per common share, basic & diluted was $0.66 against net loss per common share, basic & diluted of $0.65 a year ago. For the full year, the company reported Loss from operations was $112,895,000 against loss from operations of $29,389,000 a year ago. Net loss was $112,387,000 against net loss of $29,621,000 a year ago. Net loss per common share, basic & diluted was $2.8 against net loss per common share, basic & diluted of $1.29 a year ago.

Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease

Ardelyx, Inc. reported that the Phase 3 clinical trial evaluating the efficacy and safety of tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis met its primary endpoint and was generally well-tolerated. The responder population (n=80 out of 164) had a mean reduction in serum phosphorus from baseline to the end of the eight-week treatment period of 2.56 mg/dL, with a reduction of up to 5.7 mg/dL. Notably, in this group, 33% of patients had a reduction in serum phosphorus of greater than 3 mg/dL. The study demonstrated a statistically significant difference in serum phosphorus levels from the end of the eight-week treatment period to the end of the four-week randomized withdrawal period between the tenapanor-treated group and the placebo-treated group in the responder patient population (mean -1.01 mg/dL, median of -1.3 mg/dL) and met its primary endpoint (95% CI -1.44, -0.21; LSmean -0.82 mg/dL; p=0.01). Only 7.8% of patients discontinued treatment due to GI side effects. Hyperphosphatemia is a condition of higher than normal levels of serum phosphorus in the blood that is estimated to affect more than 745,000 people with ESRD who are on dialysis in major developed countries. The results from this trial support Ardelyx's plans to initiate the second Phase 3 study of tenapanor for the treatment of hyperphosphatemia in ESRD patients on dialysis in mid-2017. This Phase 3 study will include a 26-week open-label treatment period, with a randomized withdrawal period followed by an additional 26-week long-term safety extension.

Ardelyx, Inc. - Special Call

To discuss the Phase 3 findings

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 14, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ardelyx, Inc., please visit www.ardelyx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.